Featured Jobs
|
Strategic Retirement Plan Consultant Retirement Plan Consultants
|
|
Sentinel Group
|
|
MAP Retirement
|
|
BPAS
|
|
MAP Retirement
|
|
Defined Benefit Plan Consultant/Actuarial Analyst Sentinel Group
|
|
DWC - The 401(k) Experts
|
|
Regional Vice President, Sales MAP Retirement
|
|
Plan Administrator, Defined Benefit & Cash Balance The Pension Source
|
|
Pattison Pension
|
|
Retirement Relationship Manager MAP Retirement
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
|
Who's Driving the Craze for Ozempic, Other Weight Loss Drugs?
Morning Consult 
Oct. 25, 2023 "Extensive media coverage and high obesity rates are fueling interest in prescription weight loss drugs ... 28% of U.S. adults said they are interested in taking prescription GLP-1 drugs like Ozempic, Mounjaro or Wegovy for weight loss ... Consumers who have heard 'a lot' about the drugs, have weight-related health conditions or have higher incomes are most likely to be interested in taking the medications." |
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
| An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |